Switch to

New Website
Skip to content
Call Us Today! +880-2-41054005/10|info@beaconpharma.com.bd
  • Investors Diary
  • Careers
    • Current Openings
    • Working at Beacon
    • Apply Now
  • Language
    • English
    • Español
    • Français
    • português
    • 中文
    • русский
    • العربية
  • News Room
    • Medical Journals
  • Webmail
  • Contact Us
Beacon Pharmaceuticals PLC Logo Beacon Pharmaceuticals PLC Logo
  • Home
  • About Us
    • Beacon at a Glance
    • Guiding Principles
    • Board of Directors
    • Management Team
    • Our People
    • CSR
  • Products
    • Product Lists
    • General Products
    • Oncology Products
    • Anti Viral Products
    • Biotech Products
  • Facilities
    • Present Facilities
    • Upcoming Facilities
    • Quality Policy
    • Research & Development
    • Waste Management
  • Global Operations
  • Quick Order

Xelpac 300 mg

Home » oncology » Microtubule inhibitors » Paclitaxel (Xelpac) » Xelpac 300 mg
Previous

Xelpac 300 mg

By BPL|2016-03-24T06:52:49+00:00March 24th, 2016|Comments Off on Xelpac 300 mg

Share This Story, Choose Your Platform!

facebooktwitterlinkedin

About the Author: BPL

  • About Us
  • Guiding Principles
  • Management Team
  • Our People
  • Facilities
  • Present Facilities
  • Quality Policy
  • Research & Development
  • Waste Management
  • Products
  • General Products
  • Oncology Products
  • Biotech Products
  • Product Lists

Contact Info

BEACON Business Centre
9/B/2,Toyenbee Circular Road,
Motijheel,Dhaka-1223, Bangladesh
Phone: +880-2-41054005/10
E-mail:info@beaconpharma.com.bd
Web:www.beaconpharma.com.bd

Copyright © 2024 Beacon Pharmaceuticals PLC | All Rights Reserved | Privacy Policy | Terms & Conditions
facebooktwitterlinkedinpinterest
Toggle Sliding Bar Area